← Eichor
Study identifier: NCT05776979 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Condition: Multiple Myeloma  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 2
Planned participants61
Who can joinAll sexes, 18 Years to 72 Years
Healthy volunteersNo

About this study

To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).

This description comes directly from the study's public registry record.

Talk to the study team

Muzzaffar Qazilbash, MD  ·  (713) 745-3458  ·  mqazilba@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

M D Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05776979